Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia

Cell Reports

Volumn 14, Issue 8, 2016, Pages 1953-1965

  Danis, Etienne ^a   Yamauchi, Taylor ^a   Echanique, Kristen ^a   Zhang, Xi ^a   Haladyna, Jessica N ^a   Riedel, Simone S ^a   Zhu, Nan ^b   Xie, Huafeng ^c   Orkin, Stuart H ^c   Armstrong, Scott A ^d   Bernt, Kathrin M ^a,e   Neff, Tobias ^a,e  

^a Children's Hospital Colorado   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSINE; RAN PROTEIN; SERINE; STAT3 PROTEIN; TRANSCRIPTION FACTOR EZH2; TYROSINE; EED PROTEIN, MOUSE; EZH2 PROTEIN, MOUSE; HISTONE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN-6, MOUSE; JAK1 PROTEIN, MOUSE; JANUS KINASE 1; POLYCOMB REPRESSIVE COMPLEX 2; STAT3 PROTEIN, MOUSE; SUZ12 PROTEIN, MOUSE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CANCER STEM CELL; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; EZH2 GENE; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE LOSS; GENE SILENCING; GENETIC TRANSCRIPTION; HOMOZYGOTE; LEUKEMOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; PRE T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEM CELL; T CELL LEUKEMIA; THYMOCYTE; TRANSCRIPTION INITIATION; ANIMAL; DEFICIENCY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; ONCOGENE RAS; PATHOLOGY; PHOSPHORYLATION; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, RAS; HISTONES; HUMANS; INTERLEUKIN-6; JANUS KINASE 1; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; POLYCOMB REPRESSIVE COMPLEX 2; PRECURSOR CELLS, T-LYMPHOID; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 84959182180     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.01.064     Document Type: Article

References (72)

1. Béguelin W., Popovic R., Teater M., Jiang Y., Bunting K.L., Rosen M., Shen H., Yang S.N., Wang L., Ezponda T., et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013, 23:677-692.
2. Bell J.J., Bhandoola A. The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature 2008, 452:764-767.
3. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
4. Caganova M., Carrisi C., Varano G., Mainoldi F., Zanardi F., Germain P.L., George L., Alberghini F., Ferrarini L., Talukder A.K., et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J. Clin. Invest. 2013, 123:5009-5022.
5. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, 368:2059-2074. Cancer Genome Atlas Research Network.
6. Chambers S.M., Boles N.C., Lin K.Y., Tierney M.P., Bowman T.V., Bradfute S.B., Chen A.J., Merchant A.A., Sirin O., Weksberg D.C., et al. Hematopoietic fingerprints: an expression database of stem cells and their progeny. Cell Stem Cell 2007, 1:578-591.
7. Chen X., Skutt-Kakaria K., Davison J., Ou Y.L., Choi E., Malik P., Loeb K., Wood B., Georges G., Torok-Storb B., Paddison P.J. G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev. 2012, 26:2499-2511.
8. Coustan-Smith E., Mullighan C.G., Onciu M., Behm F.G., Raimondi S.C., Pei D., Cheng C., Su X., Rubnitz J.E., Basso G., et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009, 10:147-156.
9. Danis E., Yamauchi T., Echanique K., Haladyna J., Kalkur R., Riedel S., Zhu N., Xie H., Bernt K.M., Orkin S.H., et al. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model. Exp. Hematol. 2015, 43:930-935.
10. Dasgupta M., Dermawan J.K., Willard B., Stark G.R. STAT3-driven transcription depends upon the dimethylation of K49 by EZH2. Proc. Natl. Acad. Sci. USA 2015, 112:3985-3990.
11. De Raedt T., Beert E., Pasmant E., Luscan A., Brems H., Ortonne N., Helin K., Hornick J.L., Mautner V., Kehrer-Sawatzki H., et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 2014, 514:247-251.
12. Degryse S., de Bock C.E., Cox L., Demeyer S., Gielen O., Mentens N., Jacobs K., Geerdens E., Gianfelici V., Hulselmans G., et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood 2014, 124:3092-3100.
13. Eppert K., Takenaka K., Lechman E.R., Waldron L., Nilsson B., van Galen P., Metzeler K.H., Poeppl A., Ling V., Beyene J., et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 2011, 17:1086-1093.
14. Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C., Jones A.V., Waghorn K., Zoi K., Ross F.M., Reiter A., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 2010, 42:722-726.
15. Feng J., Liu T., Qin B., Zhang Y., Liu X.S. Identifying ChIP-seq enrichment using MACS. Nat. Protoc. 2012, 7:1728-1740.
16. Grossmann V., Bacher U., Kohlmann A., Artusi V., Klein H.U., Dugas M., Schnittger S., Alpermann T., Kern W., Haferlach T., Haferlach C. EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia. Br. J. Haematol. 2012, 157:387-390.
17. Guglielmelli P., Biamonte F., Score J., Hidalgo-Curtis C., Cervantes F., Maffioli M., Fanelli T., Ernst T., Winkelman N., Jones A.V., et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011, 118:5227-5234.
18. Haydu J.E., Ferrando A.A. Early T-cell precursor acute lymphoblastic leukaemia. Curr. Opin. Hematol. 2013, 20:369-373.
19. Hidalgo I., Herrera-Merchan A., Ligos J.M., Carramolino L., Nuñez J., Martinez F., Dominguez O., Torres M., Gonzalez S. Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest. Cell Stem Cell 2012, 11:649-662.
20. Kerenyi M.A., Shao Z., Hsu Y.J., Guo G., Luc S., O'Brien K., Fujiwara Y., Peng C., Nguyen M., Orkin S.H. Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. eLife 2013, 2:e00633.
21. Kim E., Kim M., Woo D.H., Shin Y., Shin J., Chang N., Oh Y.T., Kim H., Rheey J., Nakano I., et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013, 23:839-852.
22. Kim K.H., Kim W., Howard T.P., Vazquez F., Tsherniak A., Wu J.N., Wang W., Haswell J.R., Walensky L.D., Hahn W.C., et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 2015, 21:1491-1496.
23. Knutson S.K., Wigle T.J., Warholic N.M., Sneeringer C.J., Allain C.J., Klaus C.R., Sacks J.D., Raimondi A., Majer C.R., Song J., et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 2012, 8:890-896.
24. Knutson S.K., Warholic N.M., Wigle T.J., Klaus C.R., Allain C.J., Raimondi A., Porter Scott M., Chesworth R., Moyer M.P., Copeland R.A., et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA 2013, 110:7922-7927.
25. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., Levine J.E., Wang J., Hahn W.C., Gilliland D.G., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
26. Krivtsov A.V., Figueroa M.E., Sinha A.U., Stubbs M.C., Feng Z., Valk P.J., Delwel R., Dohner K., Bullinger L., Kung A.L., et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia 2013, 27:852-860.
27. LaFave L.M., Béguelin W., Koche R., Teater M., Spitzer B., Chramiec A., Papalexi E., Keller M.D., Hricik T., Konstantinoff K., et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat. Med. 2015, 21:1344-1349.
28. Laugesen A., Helin K. Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell 2014, 14:735-751.
29. Liu Y., Li P.K., Li C., Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J. Biol. Chem. 2010, 285:27429-27439.
30. Margueron R., Li G., Sarma K., Blais A., Zavadil J., Woodcock C.L., Dynlacht B.D., Reinberg D. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 2008, 32:503-518.
31. Maude S.L., Dolai S., Delgado-Martin C., Vincent T., Robbins A., Selvanathan A., Ryan T., Hall J., Wood A.C., Tasian S.K., et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood 2015, 125:1759-1767.
32. McCabe M.T., Ott H.M., Ganji G., Korenchuk S., Thompson C., Van Aller G.S., Liu Y., Graves A.P., Della Pietra A., Diaz E., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
33. McLemore M.L., Grewal S., Liu F., Archambault A., Poursine-Laurent J., Haug J., Link D.C. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 2001, 14:193-204.
34. Mead A.J., Kharazi S., Atkinson D., Macaulay I., Pecquet C., Loughran S., Lutteropp M., Woll P., Chowdhury O., Luc S., et al. FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors. Cell Rep. 2013, 3:1766-1776.
35. Mozzetta C., Pontis J., Fritsch L., Robin P., Portoso M., Proux C., Margueron R., Ait-Si-Ali S. The histone H3 lysine 9 methyltransferases G9a and GLP regulate polycomb repressive complex 2-mediated gene silencing. Mol. Cell 2014, 53:277-289.
36. Muto T., Sashida G., Oshima M., Wendt G.R., Mochizuki-Kashio M., Nagata Y., Sanada M., Miyagi S., Saraya A., Kamio A., et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J. Exp. Med. 2013, 210:2627-2639.
37. Neff T., Sinha A.U., Kluk M.J., Zhu N., Khattab M.H., Stein L., Xie H., Orkin S.H., Armstrong S.A. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc. Natl. Acad. Sci. USA 2012, 109:5028-5033.
38. Nikolaev S.I., Santoni F., Vannier A., Falconnet E., Giarin E., Basso G., Hoischen A., Veltman J.A., Groet J., Nizetic D., Antonarakis S.E. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. Blood 2013, 122:554-561.
39. Nikoloski G., Langemeijer S.M., Kuiper R.P., Knops R., Massop M., Tönnissen E.R., van der Heijden A., Scheele T.N., Vandenberghe P., de Witte T., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 2010, 42:665-667.
40. Novershtern N., Subramanian A., Lawton L.N., Mak R.H., Haining W.N., McConkey M.E., Habib N., Yosef N., Chang C.Y., Shay T., et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 2011, 144:296-309.
41. Ntziachristos P., Tsirigos A., Van Vlierberghe P., Nedjic J., Trimarchi T., Flaherty M.S., Ferres-Marco D., da Ros V., Tang Z., Siegle J., et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 2012, 18:298-301.
42. Oguro H., Yuan J., Tanaka S., Miyagi S., Mochizuki-Kashio M., Ichikawa H., Yamazaki S., Koseki H., Nakauchi H., Iwama A. Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. J. Exp. Med. 2012, 209:445-454.
43. Okosun J., Bödör C., Wang J., Araf S., Yang C.Y., Pan C., Boller S., Cittaro D., Bozek M., Iqbal S., et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 2014, 46:176-181.
44. Oravecz A., Apostolov A., Polak K., Jost B., Le Gras S., Chan S., Kastner P. Ikaros mediates gene silencing in T cells through Polycomb repressive complex 2. Nat. Commun. 2015, 6:8823.
45. Pasini D., Bracken A.P., Hansen J.B., Capillo M., Helin K. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol. Cell. Biol. 2007, 27:3769-3779.
46. Perez-Garcia A., Ambesi-Impiombato A., Hadler M., Rigo I., LeDuc C.A., Kelly K., Jalas C., Paietta E., Racevskis J., Rowe J.M., et al. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood 2013, 122:2425-2432.
47. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
48. Redell M.S., Ruiz M.J., Gerbing R.B., Alonzo T.A., Lange B.J., Tweardy D.J., Meshinchi S. FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report. Blood 2013, 121:1083-1093. Children's Oncology Group.
49. Schmitt T.M., Zúñiga-Pflücker J.C. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 2002, 17:749-756.
50. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85:27-37.
51. Shen X., Liu Y., Hsu Y.J., Fujiwara Y., Kim J., Mao X., Yuan G.C., Orkin S.H. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 2008, 32:491-502.
52. Shi J., Wang E., Zuber J., Rappaport A., Taylor M., Johns C., Lowe S.W., Vakoc C.R. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene 2013, 32:930-938.
53. Shimozaki K., Nakajima K., Hirano T., Nagata S. Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J. Biol. Chem. 1997, 272:25184-25189.
54. Simon C., Chagraoui J., Krosl J., Gendron P., Wilhelm B., Lemieux S., Boucher G., Chagnon P., Drouin S., Lambert R., et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 2012, 26:651-656.
55. Sneeringer C.J., Scott M.P., Kuntz K.W., Knutson S.K., Pollock R.M., Richon V.M., Copeland R.A. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. USA 2010, 107:20980-20985.
56. Srinivas S., Watanabe T., Lin C.S., William C.M., Tanabe Y., Jessell T.M., Costantini F. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 2001, 1:4.
57. Stieglitz E., Taylor-Weiner A.N., Chang T.Y., Gelston L.C., Wang Y.D., Mazor T., Esquivel E., Yu A., Seepo S., Olsen S.R., et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat. Genet. 2015, 47:1326-1333.
58. Su I.H., Dobenecker M.W., Dickinson E., Oser M., Basavaraj A., Marqueron R., Viale A., Reinberg D., Wülfing C., Tarakhovsky A. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 2005, 121:425-436.
59. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
60. Tanaka S., Miyagi S., Sashida G., Chiba T., Yuan J., Mochizuki-Kashio M., Suzuki Y., Sugano S., Nakaseko C., Yokote K., et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 2012, 120:1107-1117.
61. Treanor L.M., Zhou S., Janke L., Churchman M.L., Ma Z., Lu T., Chen S.C., Mullighan C.G., Sorrentino B.P. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J. Exp. Med. 2014, 211:701-713.
62. Tsai M.C., Manor O., Wan Y., Mosammaparast N., Wang J.K., Lan F., Shi Y., Segal E., Chang H.Y. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010, 329:689-693.
63. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
64. Velu C.S., Chaubey A., Phelan J.D., Horman S.R., Wunderlich M., Guzman M.L., Jegga A.G., Zeleznik-Le N.J., Chen J., Mulloy J.C., et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J. Clin. Invest. 2014, 124:222-236.
65. Verhaak R.G., Wouters B.J., Erpelinck C.A., Abbas S., Beverloo H.B., Lugthart S., Löwenberg B., Delwel R., Valk P.J. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 2009, 94:131-134.
66. Wada H., Masuda K., Satoh R., Kakugawa K., Ikawa T., Katsura Y., Kawamoto H. Adult T-cell progenitors retain myeloid potential. Nature 2008, 452:768-772.
67. Xie H., Xu J., Hsu J.H., Nguyen M., Fujiwara Y., Peng C., Orkin S.H. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell 2014, 14:68-80.
68. Xu B., On D.M., Ma A., Parton T., Konze K.D., Pattenden S.G., Allison D.F., Cai L., Rockowitz S., Liu S., et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood 2015, 125:346-357.
69. Yoshida K., Toki T., Okuno Y., Kanezaki R., Shiraishi Y., Sato-Otsubo A., Sanada M., Park M.J., Terui K., Suzuki H., et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat. Genet. 2013, 45:1293-1299.
70. Zhang J., Ding L., Holmfeldt L., Wu G., Heatley S.L., Payne-Turner D., Easton J., Chen X., Wang J., Rusch M., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
71. Zhang J.A., Mortazavi A., Williams B.A., Wold B.J., Rothenberg E.V. Dynamic transformations of genome-wide epigenetic marking and transcriptional control establish T cell identity. Cell 2012, 149:467-482.
72. Zhang X., Yue P., Page B.D., Li T., Zhao W., Namanja A.T., Paladino D., Zhao J., Chen Y., Gunning P.T., Turkson J. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc. Natl. Acad. Sci. USA 2012, 109:9623-9628.